Monitor the outcome of the proxy vote and whether Altai gains board seats. Upcoming FDA decisions on CT/NG and Colli-Pee in 2026 will be critical catalysts. Insider buying and the repurchase program suggest management confidence, but revenue growth has not yet materialized.
Price Chart
Executive Summary
OraSure Technologies filed a definitive proxy statement (DEFA14A) in response to an activist campaign by Altai Capital, which is pushing for board representation to force a sale of the company. OraSure's management defends its transformation strategy, highlighting upcoming product launches, cost reductions, and a $40 million share buyback, while accusing Altai's founder of seeking personal control rather than shareholder value.
Key Facts
- OraSure is facing a proxy contest from activist investor Altai Capital, which seeks board representation to push for a sale.
- The company has rejected Altai's demands, stating it is at a strategic inflection point with key product launches in 2026.
- OraSure highlights operational progress: 40% workforce reduction, 37% SG&A cost cut since 2022, and ~260 bps gross margin expansion.
- The company submitted FDA applications for two high-impact STI tests targeting a $2B market.
- OraSure announced a $40 million share repurchase program and leadership stock purchases to signal confidence.
- Altai rejected settlement offers, including the appointment of its nominee John Bertrand and a board declassification proposal.
Financial Impact
$40 million share repurchase program announced; no specific revenue or earnings figures provided
Risk Factors
- Proxy contest could lead to board instability or strategic disruption.
- Failure to achieve FDA clearance for key products in 2026 would undermine growth strategy.
- Revenue growth remains forward-looking with no current financial improvement confirmed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-111262 |
| Document: 0001193125-26-111262-index-headers.html | 0001193125-26-111262 |
| Document: 0001193125-26-111262-index.html | 0001193125-26-111262 |
| Document: 0001193125-26-111262.txt | 0001193125-26-111262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 23, 2026 10w ago | Court Ruling | $4.03 $3.74 | ▼ −7.20% | ▼ −10.50% | $3.99 (−0.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.18 $4.30 | ▲ +2.75% | ▲ +0.97% | $3.99 (−4.55%) |
Jun 3, 2026 17w ago | 8-K | $4.17 $4.35 | ▲ +4.32% | ▲ +5.69% | $3.99 (−4.32%) |
May 6, 2026 21w ago | 8-K | $3.13 $3.95 | ▼ −26.20% | ▼ −23.06% | $3.99 (−27.48%) |
Apr 22, 2026 23w ago | Press Release | $3.05 $3.07 | ▼ −0.66% | ▲ +3.98% | $3.99 (−30.82%) |
Apr 17, 2026 24w ago | DEFA14A | $3.16 $2.95 | ▼ −6.65% | ▼ −12.02% | $3.99 (+26.27%) |
Apr 17, 2026 24w ago | DEFA14A | $3.16 $2.95 | ▼ −6.65% | ▼ −12.02% | $3.99 (+26.27%) |
Apr 17, 2026 24w ago | 8-K | $3.16 $2.95 | ▼ −6.65% | ▼ −12.02% | $3.99 (+26.27%) |
Mar 20, 2026 28w ago | Insider Cluster | $2.95 $3.00 | ▲ +1.53% | ▼ −7.79% | $3.99 (+35.25%) |
Mar 17, 2026 28w ago | DEFA14A | $2.90 $3.21 | ▲ +10.69% | ▲ +4.64% | $3.99 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access